Drugs / Human Menopausal Gonadotropin (hMG)
Human Menopausal Gonadotropin (hMG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00298025 Background | Sep 2003 → May 2004 | — | EMD Serono | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Menopausal Gonadotropin (hMG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00298025 ↗ |
| Modality | Protein / enzyme biologic | “Human menopausal gonadotropin (hMG)” NCT00298025 ↗ |
| Route | Subcutaneous | “Human menopausal gonadotropin (hMG) will be administered subcutaneously” NCT00298025 ↗ |